TY - JOUR
T1 - Association of metabolic syndrome and change in Unified Parkinson's Disease Rating Scale scores
AU - Leehey, Maureen
AU - Luo, Sheng
AU - Sharma, Saloni
AU - Wills, Anne Marie A.
AU - Bainbridge, Jacquelyn L.
AU - Wong, Pei Shieen
AU - Simon, David K.
AU - Schneider, Jay
AU - Zhang, Yunxi
AU - Pérez, Adriana
AU - Dhall, Rohit
AU - Christine, Chadwick W.
AU - Singer, Carlos
AU - Cambi, Franca
AU - Boyd, James T.
N1 - Funding Information:
NET-PD was funded by the National Institute of Neurological Disorders and Stroke: U01NS043127, U01NS043128, and U10NS44415-44555.
Funding Information:
M. Leehey reports no disclosures relevant to the manuscript. S. Luo received grants from the NIH, International Parkinson and Movement Disorder Society, and CHDI Foundation. S. Sharma reports no disclosures relevant to the manuscript. A. Wills serves as a consultant for Accordant and Sage Bionetworks and has received research support from the ALS Association, Pfizer, and Acorda. J. Bainbridge, P. Wong, D. Simon, J. Schneider, Y. Zhang, A. Pérez, R. Dhall, C. Christine, C. Singer, and F. Cambi report no disclosures relevant to the manuscript. J. Boyd served as a consultant and/or scientific advisor for AbbVie Inc, Auspex, Lundbeck, and Medical Education Resources and received research support from the Michael J. Fox Foundation, NIH/National Institute of Neurological Disorders and Stroke, Auspex, Biotie, CHDI Foundation, NeuroDerm, Chrono Therapeutics, and Vaccinex. Go to Neurology.org for full disclosures.
Publisher Copyright:
© 2017 The Author(s).
PY - 2017/10/24
Y1 - 2017/10/24
N2 - Objective: To explore the association between metabolic syndrome and the Unified Parkinson's Disease Rating Scale (UPDRS) scores and, secondarily, the Symbol Digit Modalities Test (SDMT). Methods: This is a secondary analysis of data from 1,022 of 1,741 participants of the National Institute of Neurological Disorders and Stroke Exploratory Clinical Trials in Parkinson Disease Long-Term Study 1, a randomized, placebo-controlled trial of creatine. Participants were categorized as having or not having metabolic syndrome on the basis of modified criteria from the National Cholesterol Education Program Adult Treatment Panel III. Those who had the same metabolic syndrome status at consecutive annual visits were included. The change in UPDRS and SDMT scores from randomization to 3 years was compared in participants with and without metabolic syndrome. Results: Participants with metabolic syndrome (n 5 396) compared to those without (n 5 626) were older (mean [SD] 63.9 [8.1] vs 59.9 [9.4] years; p<0.0001), were more likely to be male (75.3% vs 57.0%; p<0.0001), and had a higher mean uric acid level (men 5.7 [1.3] vs 5.3 [1.1] mg/dL, women 4.9 [1.3] vs 3.9 [0.9] mg/dL, p<0.0001). Participants with metabolic syndrome experienced an additional 0.6- (0.2) unit annual increase in total UPDRS (p 5 0.02) and 0.5- (0.2) unit increase in motor UPDRS (p 5 0.01) scores compared with participants without metabolic syndrome. There was no difference in the change in SDMT scores. Conclusions: Persons with Parkinson disease meeting modified criteria for metabolic syndrome experienced a greater increase in total UPDRS scores over time, mainly as a result of increases in motor scores, compared to those who did not. Further studies are needed to confirm this finding.
AB - Objective: To explore the association between metabolic syndrome and the Unified Parkinson's Disease Rating Scale (UPDRS) scores and, secondarily, the Symbol Digit Modalities Test (SDMT). Methods: This is a secondary analysis of data from 1,022 of 1,741 participants of the National Institute of Neurological Disorders and Stroke Exploratory Clinical Trials in Parkinson Disease Long-Term Study 1, a randomized, placebo-controlled trial of creatine. Participants were categorized as having or not having metabolic syndrome on the basis of modified criteria from the National Cholesterol Education Program Adult Treatment Panel III. Those who had the same metabolic syndrome status at consecutive annual visits were included. The change in UPDRS and SDMT scores from randomization to 3 years was compared in participants with and without metabolic syndrome. Results: Participants with metabolic syndrome (n 5 396) compared to those without (n 5 626) were older (mean [SD] 63.9 [8.1] vs 59.9 [9.4] years; p<0.0001), were more likely to be male (75.3% vs 57.0%; p<0.0001), and had a higher mean uric acid level (men 5.7 [1.3] vs 5.3 [1.1] mg/dL, women 4.9 [1.3] vs 3.9 [0.9] mg/dL, p<0.0001). Participants with metabolic syndrome experienced an additional 0.6- (0.2) unit annual increase in total UPDRS (p 5 0.02) and 0.5- (0.2) unit increase in motor UPDRS (p 5 0.01) scores compared with participants without metabolic syndrome. There was no difference in the change in SDMT scores. Conclusions: Persons with Parkinson disease meeting modified criteria for metabolic syndrome experienced a greater increase in total UPDRS scores over time, mainly as a result of increases in motor scores, compared to those who did not. Further studies are needed to confirm this finding.
UR - http://www.scopus.com/inward/record.url?scp=85032225043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032225043&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000004572
DO - 10.1212/WNL.0000000000004572
M3 - Article
C2 - 28972194
AN - SCOPUS:85032225043
VL - 89
SP - 1789
EP - 1794
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 17
ER -